共 43 条
- [21] FRACTURE RISK IN WOMEN ≥65 YEARS WITH ONCE-MONTHLY ORAL IBANDRONATE COMPARED WITH WEEKLY BISPHOSPHONATES: SUBANALYSIS FROM THE EVALUATION OF IBANDRONATE EFFICACY (VIBE) DATABASE STUDYOSTEOPOROSIS INTERNATIONAL, 2009, 20 : 153 - 153Silverman, S.Poston, S.Blumentals, W.Reginster, J. -Y.
- [22] BONE MINERAL DENSITY INCREASES WITH MONTHLY IV IBANDRONATE INJECTIONS CONTRIBUTE TO ITS FRACTURE RISK REDUCTION IN PRIMARY OSTEOPOROSIS: 3-YEAR ANALYSIS OF THE PHASE III MOVER STUDYOSTEOPOROSIS INTERNATIONAL, 2013, 24 : S592 - S593Hagino, H.Nakamura, T.Ito, M.Nakano, T.Hashimoto, J.Tobinai, M.Mizunuma, H.
- [23] Fracture Risk in Women Aged 65 Years or Older with Once-Monthly Oral Ibandronate Compared with Weekly Bisphosphonates: Analyses From the eValuation of IBandronate Efficacy (VIBE) Database Fracture Study.JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S465 - S465Silverman, S. L.Blumentals, W. A.Poston, S. A.Harris, S. T.
- [24] A Phase III Study of the Effects of Denosumab on Vertebral, Nonvertebral, and Hip Fracture in Women with Osteoporosis: Results from the FREEDOM TrialJOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S80 - S80Cummings, S. R.McClung, M. R.Christiansen, C.Siris, E.Adami, S.Kutilek, S.Reid, I. R.Zanchetta, J. R.Martin, J. SanLibanati, C.Siddhanti, S.Wang, A.Delmas, P. D.
- [25] Bone Mineral Density Increases with Monthly i.v. Ibandronate Injections Contribute to its Fracture Risk Reduction in Primary Osteoporosis: 3-Year Analysis of the Phase III MOVER StudyJOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28Hagino, HiroshiNakamura, ToshitakaIto, MasakoNakano, TetsuoHashimoto, JunkoTobinai, MasatoMizunuma, Hideki
- [26] Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trialJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08): : 3609 - 3617Delmas, PDEnsrud, KEAdachi, JDHarper, KDSarkar, SGennari, CReginster, JYPols, HAPRecker, RRHarris, STWu, WTGenant, HKBlack, DMEastell, R
- [27] Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practiceJournal of Bone and Mineral Metabolism, 2017, 35 : 419 - 427Satoshi SoenTakashi UmemuraTsuyoshi AndoToshiaki KamisakiMasahiko NishikawaRyoichi MuraokaYoshinori IkedaKyoko TakedaMitsuharu OsawaToshitaka Nakamura
- [28] Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practiceJOURNAL OF BONE AND MINERAL METABOLISM, 2017, 35 (04) : 419 - 427Soen, SatoshiUmemura, TakashiAndo, TsuyoshiKamisaki, ToshiakiNishikawa, MasahikoMuraoka, RyoichiIkeda, YoshinoriTakeda, KyokoOsawa, MitsuharuNakamura, Toshitaka
- [29] CONVERSION FROM TACROLIMUS CAPSULES TWICE DAILY TO TACROLIMUS TABLETS ONCE DAILY IN STABLE KIDNEY TRANSPLANT PATIENTS: EFFICACY RESULTS FROM A PHASE III, OPEN-LABEL, MULTICENTER, PROSPECTIVE, RANDOMIZED STUDYTRANSPLANT INTERNATIONAL, 2011, 24 : 227 - 227Rostaing, L.Ciechanowski, K.Bunnapradist, S.Mulgaonkar, S.
- [30] EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDYJOURNAL OF HEPATOLOGY, 2013, 58 : S326 - S326Buti, M.Agarwal, K.Horsmans, Y.Sievert, W.Janczewska, E.Zeuzem, S.Nyberg, L.Brown, R. S., Jr.Hezode, C.Rizzetto, M.Parana, R.De Meyer, S.DeMasi, R.Luo, D.Witek, J.